RESORCE Trial: Role of Regorafenib in Unresectable HCC Treatment

RESORCE Trial: Role of Regorafenib in Unresectable HCC Treatment

User Photo
obr

3 years
773 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses the date of the RESORCE Trial and how it changed the role of regorafenib in the treatment of unresectable HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Up Next Autoplay